Dynamics of SARS-CoV-2 immunity after vaccination and breakthrough infection in rituximab-treated rheumatoid arthritis patients: a prospective cohort study

BackgroundSARS-CoV-2 vaccination in rheumatoid arthritis (RA) patients treated with B cell-depleting drugs induced limited seroconversion but robust cellular response. We aimed to document specific T and B cell immunity in response to vaccine booster doses and breakthrough infection (BTI).MethodsWe...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Hassen Kared, Ingrid Jyssum, Amin Alirezaylavasani, Ingrid M. Egner, Trung The Tran, Lisa Tietze, Katrine Persgård Lund, Anne Therese Tveter, Sella A. Provan, Hilde Ørbo, Espen A. Haavardsholm, John Torgils Vaage, Kristin Jørgensen, Silje Watterdal Syversen, Fridtjof Lund-Johansen, Guro Løvik Goll, Ludvig A. Munthe
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Frontiers Media S.A. 2024-02-01
Rangatū:	Frontiers in Immunology
Ngā marau:	T cell B cell COVID-19 mRNA vaccination rheumatoid arthritis rituximab
Urunga tuihono:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1296273/full
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!